Related Experiment Videos
DNA- versus RNA-based methods for human papillomavirus detection in cervical neoplasia
1Department of Pathology, The Norwegian Radium Hospital, Oslo, Norway. agneskathrine.lie@ahus.no
Gynecologic Oncology
|June 10, 2005
Summary
This study compared DNA and mRNA HPV tests for detecting high-grade cervical neoplasia. The DNA test detected more high-grade lesions, but the mRNA test showed higher specificity for risk evaluation in Norwegian women.
Area of Science:
- Gynecology
- Oncology
- Virology
Background:
- Cervical cancer screening relies on cytology and HPV testing.
- Accurate detection of high-grade cervical neoplasia (CIN2+) is crucial for effective management.
- Comparing different HPV detection methods (DNA vs. mRNA) can optimize screening protocols.
Purpose of the Study:
- To compare the diagnostic performance of DNA-based and mRNA-based human papillomavirus (HPV) testing methods.
- To evaluate their utility in detecting high-grade cervical neoplasia (CIN2+) in a Norwegian population.
- To assess the specificity of each test in identifying women who would benefit from risk-evaluation.
Main Methods:
- Analysis of HPV prevalence in 383 women with positive index cytology.
- Utilized two commercial HPV tests: Hybrid Capture II (DNA-based) and Pre Tect HPV-Proofer (mRNA-based).
- Retesting with PCR and sequencing for discordant cases and latent/transient infections.
Main Results:
- High-risk HPV detected in 99.7% of histological high-grade lesions (CIN2+).
- DNA test positive in 95% (275/291), mRNA test positive in 77% (225/291) of CIN2+ cases.
- mRNA test identified 83% of women with normal cytology but high-grade histology; DNA test showed higher false positives in benign lesions.
Conclusions:
- Both HPV tests show potential for improving high-grade cervical neoplasia detection.
- The mRNA test appears more suitable for risk-evaluation due to higher specificity.
- Further large-scale, population-based studies are needed to validate HPV testing in Norway.